Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of ribonucleic acid interference (RNAi)-based pharmaceuticals. It develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, chronic liver, and complement-mediated diseases, as well as neurodegenerative diseases and pain. The company’s principal development programs include Nedosiran for primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; Belcesiran for alpha-1 antitrypsin deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. It has collaboration agreements with Novo Nordisk A/S; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Eli Lilly, and Company; Alexion Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH; and Alnylam Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc. was formerly known as Oncorna Pharmaceuticals, Inc. and changed its name to Dicerna Pharmaceuticals, Inc. on April 19, 2007. The company was incorporated in 2006 and is based in Lexington, Massachusetts with additional offices in Boulder, Colorado, and Lexington, Massachusetts. As of December 28, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.